DEPODRAG 5 ml

SPECIES

Dogs and cats.

DOSAGE FORM

Injectable suspension.

THERAPEUTIC ACTION

Steroidal anti-inflammatory.

COMPOSITION

Each 1 mL of suspension contains:
Triamcinolone Acetonide…………… 6 mg
Excipients q.s.p……………………….1 mL

INDICATIONS

Anti-inflammatory of long lasting effect for allergic and dermatologic disorders and arthritis.

ROUTE OD ADMINISTRATION AND DOSAGE

Administration route: Intramuscular, subcutaneous, intra-articular e intrasynovial.

Dose of the active principle:
Dogs and cats:
– In allergy symptoms: 0.2 mg / Kg, in a single dose. In severe cases, it can be administered up to 1 mg / Kg, in a single dose.
– In intra-articular and intrasynovial treatment: 1 to 3 mg / Kg, in a single dose, repeated if necessary after 3 to 4 days.

Product dosage:
Dogs and cats:
– In allergy : 0.2 mL every 6 Kg of weight, in a single dose. In severe cases, up to 1 mL can be administered every 6 kg of weight, in a single dose.
– In intra-articular and intrasynovial treatment: 0.2 to 0.5 mL, in a single dose, repeated if necessary after 3 to 4 days.
It is not advisable to repeat the treatment beyond three consecutive times.

DRUG INTERACTIONS

• Amphotericin B or caliuretic diuretics (Furosemide, Thiazides) can cause hypokalaemia when administered concomitantly with glucocorticoids. When these drugs are used simultaneously with digitalis glycosides, the possibility of toxicity may be increased if hypokalemia develops. Diligent monitoring of potassium and digitalis levels is recommended.
• Glucocorticoids can lower blood levels of salicylates.
• Insulin requirements may increase in patients receiving glucocorticoids.
• Phenytoin, Phenobarbital, Rifampicin can increase glucocorticoid metabolism.
• The concomitant administration of glucocorticoids and cyclosporine can increase the blood levels of each, with mutual inhibition of hepatic metabolism. The clinical significance of this interaction is uncertain. Glucocorticoids can also inhibit the hepatic metabolism of cyclophosphamide. Dosage adjustments may be required.
• Mitotane can alter steroid metabolism; Higher than usual doses may be necessary to treat mitotane-induced adrenal insufficiency.
• Patients treated with corticosteroids at immunosuppressive doses should not receive live attenuated live virus vaccines because viral replication may be enhanced. A lowered immune response can occur after administration of a vaccine, toxoid, or bacterin, in patients receiving glucocorticoids.
• Administration of ulcerogenic drugs (eg, non-steroidal anti-inflammatory drugs) with glucocorticoids may increase the risk of gastrointestinal ulceration.
• The effects of hydrocortisone, and possibly other glucocorticoids, can be potentiated by concomitant administration with estrogens.
• In patients with Myasthenia gravis, concomitant administration of glucocorticoids and anticholinesterases (eg, Pyridostigmine, Neostigmine, etc.) can induce pronounced muscle weakness. If possible, discontinue anticholinesterase medication for at least 24 hours before glucocorticoid administration.

CONTRAINDICATIONS

• Do not use in viral infectious processes and generalized fungal infections.
• Do not use in musculoskeletal disorders where immobility is required.
• Do not use in animals with tuberculosis, chronic nephritis or Cushing’s syndrome, except for emergency therapy.
• Do not use in case of bone metaplasia and osteoporosis.
• Do not use in patients with diabetes mellitus, kidney or heart failure.
• Do not use in patients with hypersensitivity to the active substance.
• Do not use in animals with gastrointestinal or corneal ulcer.
• Do not use in pregnant or lactating females.

SPECIAL PRECAUTIONS FOR USE

Special warnings and precautions for use:

• In bacterial infections, the use must be associated with antibacterials.
• Corticosteroids can precipitate labor during the final stages of pregnancy.
• Shake before using.
• Keep out of the reach of children.

SPECIAL PRECAUTIONS FOR THE OPERATOR

• The product is irritating in the case of contact with the eyes. It can be dangerous in the case of accidental ingestion and in the case of contact with the skin.
• Pregnant women should not handle the product.

ADVERSE EFFECTS

Unwanted effects and adverse reactions:
Long-term use of Depodrag^® may cause suppressive effects on the hypothalamic-pituitary-adrenal axis leading to adrenal atrophy (adrenal insufficiency). It can also cause bone resorption or inhibition of bone growth and repair, inhibition of collagen synthesis, decreased growth rate, delayed healing, diarrhea, gastrointestinal irritation, gastrointestinal ulceration, hematopoietic changes, sodium and sodium retention. fluid and flare-up of latent infections.
The most common side effects are polyuria, polydipsia, polyphagia, lethargy, weakness, and bilateral alopecia. Less common are weight loss, anorexia, and diarrhea.

OBSERVATIONS

Do not use in pregnant and lactating females.

• Glucocorticoids are probably necessary for normal fetal development. They may be required for proper surfactant production and development of myelin, retina, pancreas, and breasts.
• Excessive doses early in gestation can lead to teratogenic effects. The administration of exogenous steroids can induce labor when used in the final stages of pregnancy. It is recommended not to use high doses in pregnant animals.
• Glucocorticoids not bound to plasma proteins enter the milk. High doses or prolonged administration to mothers can potentially inhibit the growth of newborns.

Special precautions for disposal of unused product or waste material:
Discard any unused product remains in its original container. Dispose of the waste of this product with care together with household waste.
Uruguay: Dispose of the product container at the nearest collection center.

CONSERVATION

Store at a temperature between 2 ° and 30 ° C, protected from light. Once opened use within 3 months. Discard the unused product after that period of time.

CONDITION OF SALE

To be supply only on veterinary prescription.

PRESENTATION

5 mL and 20 mL vial

PREPARED BY

Drag Pharma Laboratory.

RECORDS

• Chile: Reg. SAG Nº 0529
• Uruguay: Reg. N° MGAP A-4493
• Rep. Dominicana: Reg. Nº 5607
• Panamá: Reg. Nº RF-4183-19
• Bolivia: Reg. SENASAG CR-PUV Nº 005515/13
• Perú: Reg. SENASA F.06.42.I.0240

COUNTRIES WHERE IT IS MARKETED

Imported and distributed in Bolivia by:
AGROGUARANI SRL.
Santa Cruz de la Sierra, Bolivia
TEL: + (591) 314-1401

Imported in Uruguay:
VIVAFIL S.A.
Rio Negro 1107 Montevideo – Uruguay, TEL 29001112
grupotecnovet@gmail.com
Technical Director: DMTV Diego Cuadrado.

Imported and distributed in Peru by:
Representaciones Durand SAC.
Av. Manuel Olguín No. 501 Office No. 604 Santiago de Surco Lima.